Fecal Microbiota Transplantation
1
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Bristol Myers SquibbPRINCETON, NJ
1 programAllogenic Fecal Microbiota TransplantationN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
MaaT Pharmafecal microbiota transfer
BiomeBankAntibiotics
Bristol Myers SquibbAllogenic Fecal Microbiota Transplantation
Clinical Trials (3)
Total enrollment: 149 patients across 3 trials
Treatment of Steroid Refractory Gastro-intestinal Acute GVHD afteR AllogeneiC HSCT With fEcal Microbiota tranSfer
Start: Aug 2018Est. completion: Nov 202024 patients
Phase 2Completed
Microbial Restoration in Inflammatory Bowel Diseases
Start: May 2022Est. completion: Apr 2026120 patients
Phase 1/2Recruiting
The IRMI-FMT Trial
Start: May 2021Est. completion: Jun 20235 patients
N/ATerminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 149 patients
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.